
Sandoz launches allergy relief nasal spray in Germany and Switzerland
pharmafile | April 9, 2026 | News story | | Ear Nose & throat
Sandoz has launched its azelastine and fluticasone fixed-dose-combination (FDC) nasal spray in Germany and Switzerland.
In Germany the FDC over the-counter (OTC) nasal spray is used to treat the symptoms of moderate-to-severe seasonal allergic rhinitis in adults.
The treatment is approved in Switzerland for seasonal allergic rhinitis and rhino conjunctivitis in patients aged six years and older, and moderate-to-severe perennial allergic rhinitis and rhino conjunctivitis in patients 12 years and older.
Affecting between 15 to 20% of the Swiss population, allergic rhinitis affects up to 15 million people in Germany.
Providing an alternative to the reference medicine, the azelastine and fluticasone FDC nasal spray is being introduced to the OTC allergy segment in Germany and to the Sandoz antihistaminic portfolio in Switzerland.
Christophe Delenta, President Europe, Sandoz, said: “Seasonal allergies can have a real impact on patients, affecting sleep, concentration, productivity and overall quality of life.
“With the launch of our azelastine/fluticasone combination spray, Sandoz is expanding access for German and Swiss patients ahead of the 2026 allergy season, while also strengthening our position in allergy care.”
By adding the nasal spray to its portfolio, Sandoz aims to strengthen and expand its offering in this therapeutic area.






